CN107828741A - The dual-gene missing low virulent strain of pseudorabies virus and its application - Google Patents
The dual-gene missing low virulent strain of pseudorabies virus and its application Download PDFInfo
- Publication number
- CN107828741A CN107828741A CN201711083192.7A CN201711083192A CN107828741A CN 107828741 A CN107828741 A CN 107828741A CN 201711083192 A CN201711083192 A CN 201711083192A CN 107828741 A CN107828741 A CN 107828741A
- Authority
- CN
- China
- Prior art keywords
- prv
- strains
- gene
- pseudorabies virus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16751—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides the dual-gene missing low virulent strain of pseudorabies virus and its application, belongs to the vaccines arts of animal medicine.80 plants of pseudorabies virus LA1206, deposit number are:CGMCC No.14329.The present invention also provides the dual-gene application for lacking low virulent strain in pseudorabies vaccines are prepared of pseudorabies virus, a kind of recombinant vector live vaccine.The recombinant vector obtains after external source protective antigen gene expression cassette is inserted in the low virulent strain genome.The live vaccine that 80 plants of PRV LA1206, available for the early immune of newborn piglet, blocks the infection of wild poison as early as possible to the safety of 1 age in days newborn piglet 100%.Can quickly produce efficient protection, the especially vaccine after inoculation wean PRV feminine gender piglets can not only prevent to fall ill, moreover it is possible to prevent toxin expelling.By being monitored to PRV gE and gB antibody, it is very beneficial for the purification to PRV variants.
Description
Technical field
The invention belongs to the vaccines arts of animal medicine, and in particular to pseudorabies virus it is dual-gene missing low virulent strain and its
Using.
Background technology
Pseudoabies is a kind of acute, strong biography caused by pseudorabies virus (Pseudorabies Virus, PRV)
Catch an illness.The classical symptom that pseudoabies shows as very itching often, and heating and brain ridge occur for the domestic animals such as ox, sheep and wild animal
The clinical symptoms such as marrow inflammation.And the symptom that pseudoabies occurs for pig is age-related, sow is often miscarried;Newborn piglet has nerve
Symptom, the death rate are high;Growing and fattening pigs are mainly respiratory symptom, and Adult Pig infects growth retardation after Pseudorabies virus, do not sent out generally
Life and death is died.Invention and large-scale promotion due to PRV gene delections strain vaccine (the Bartha K61 strains of such as gE gene delections)
Use, and coordinate and differentiate immune swine and the foundation and application of the ELISA detection method of the PRV gE antibody of wild virus infection pig, pass through
Positive boar is persistently eliminated, many countries realize the purification of the pseudorabies virus in domestic pig group in the world, in China, are permitted
More pig farms have also been successfully established the swinery of PRV gE negative antibodies, and many pig farms realize PRV purification, porcine pseudorabies substantially
Preferable control is obtained.
Since 2011, there is pig puppet on a large scale in many pig farms that traditional pseudorabies disease vaccine was immunized of northern China
Rabies, epidemic situation is rapidly to the most of pig farm sprawling in the whole nation afterwards, and PRV gE antibody positive rates remain high, to China
Pig industry causes to seriously endanger.The result of study of multiple team proves that this wheel epidemic situation is caused by the PRV street strains to make a variation, the change
The pathogenic of different strain significantly increases, its major antigen gene have with traditional vaccine strain it is significantly different, for more effectively tackle PRV become
The harm of different strain, protection can be improved using variant development, and can antidiastole immune swine is new with wild virus infection pig
Vaccine is the key of current China's porcine pseudorabies prevention and control.But the security of existing variation strain live vaccine is high not enough.Example
Such as, disclosed in the patent of invention of Application No. 201510388390.9 by knocking out the wild malicious AH02LA strains gE of pseudorabies virus
The LA-A strains obtained after gene, the vaccine prepared using the strain is to the protecting effect of pseudorabies virus variant 100%, especially
It is that the vaccine can not only prevent to fall ill, moreover it is possible to prevent toxin expelling, still, the strain is only to 4 week old piglets safety.
The content of the invention
It is an object of the invention to provide the dual-gene missing low virulent strain of pseudorabies virus, the strain can be good at adapting to ST
Cell, titre is high, and virulence significantly reduces, and to 1 age in days piglet no pathogenicity, therefore is to have the vaccine candidate of higher-security weak
Strain.
The dual-gene missing low virulent strain of pseudorabies virus, is pseudorabies virus LA1206-80 strains, and deposit number is:
CGMCC No.14329。
It is a further object of the present invention to provide the dual-gene missing low virulent strain of pseudorabies virus to prepare pseudorabies vaccines
In application, using immune pig can be provided 100% protection after the vaccine immunity, can not only prevent to fall ill, moreover it is possible to prevent
Toxin expelling, because the strain virulence significantly reduces, to 1 age in days piglet no pathogenicity, therefore it can be used for the early immune of newborn piglet,
The infection of wild poison is blocked as early as possible, and the live vaccine has higher security.
Another object of the present invention is to provide the vaccine using the dual-gene missing low virulent strain of pseudorabies virus as active component.
Using the vaccine of pseudorabies virus LA1206-80 strains to 1 age in days newborn piglet safety, the negative susceptible piglets of inoculation wean PRV
Can reach within 7 days afterwards can not only prevent to fall ill to the protecting effect of pseudorabies virus variant 100%, the especially vaccine, also
Toxin expelling can be prevented, unexpected technique effect is all achieved in security and immune efficacy.By being monitored to antibody,
Animal and the infection animal of the immune vaccine can be distinguished, is advantageous to the purification to PRV variants.
The present invention also provides a kind of recombinant vector live vaccine, and its active component is the dual-gene missing of the pseudorabies virus
Insert what is obtained after external source protective antigen gene expression cassette in low virulent strain genome.Promoter can select pMCMV IE,
SV40 and pHCMV IE etc., the insertion point of foreign gene includes between the UL22 and UL21 of genome, between UL46 and UL27,
Between UL51 and UL50, between UL35 and UL36, between UL40 and UL41, between UL44 and UL26.5 between UL4 and UL3.5
Noncoding region, the foreign gene of insertion includes the E protein gene of CSFV, the Cap protein gene of pig circular ring virus, mad dog
The G-protein gene of sick virus, the VP1 genes of foot and mouth disease virus, the VP60 genes of the HA genes of swine influenza virus and Rabbit pest virus
Deng.
Live vaccine of the present invention, it is using pseudorabies virus LA1206-80 strains as active component, can be added in vaccine immune
Adjuvant and vaccine excipients etc., those skilled in the art can easily be produced.
Applicant obtains one plant of pseudorabies virus gene delection low virulent strain by a large amount of creative work,
That is PRV LA1206-80 strains.LA1206-80 strain gC and gD genes and completely the same (the gC genes GenBank of AH02LA strains:
KR605320;GD genes GenBank:KR605321), with now disclosing variation strain's very high homology.Pseudoabies disease of the present invention
Malicious LA1206-80 strains are first by PRV AH02LA strain gE genes (GenBank:KR605321) the 13rd~1298 bit base strikes
Remove, be further continued for knocking out TK genes (SEQ ID No:1) the 184th~530 bit base, then weak rear clone is caused to screen through passage
And obtain.Pseudorabies virus LA1206-80 strains can be well adapted for ST cells, and growth titre is up to 108.5TCID50/mL.It is pseudo-
The live vaccine of hydrophobin LA1206 strains is to the safety of 1 age in days newborn piglet 100%, available for the early immune of newborn piglet,
The infection of wild poison is blocked as early as possible.Efficient protection can be quickly produced after inoculation wean PRV feminine gender piglets, pseudorabies virus is become
Different strain 100% is protected, and especially the vaccine can not only prevent to fall ill, moreover it is possible to is prevented toxin expelling, is achieved unexpected technology effect
Fruit.By being monitored to PRV gE and gB antibody, animal and the infection animal of the immune vaccine can be distinguished, is very beneficial for
Purification to PRV variants.It is used as the protective antigens of the live vector expression susceptible cause of disease of pig, moreover it is possible to reach one pin of inoculation and prevent
The effect of two or more epidemic diseases.
Brief description of the drawings
Fig. 1, transfer vector pPRV (AH02LA)-GFP (gE-) structure chart.
Fig. 2, transfer vector pPRV (AH02LA)-gE Δs structure chart.
Fig. 3, pseudorabies virus PRV AH02LA (Δ gE) strain structure schematic diagram.(A) PRV AH02LA strains are shown
Genome, ULRefer to unique long area, UsRefer to unique short area, IR and TR refer to internal and end duplicate block respectively.(B) it show by upper
Trip homology arm Δ gE-H1 and downstream homology arm Δ gE-H2 carries out the partial order that homologous recombination replaces GFP expression cassettes gE genes
Row.(C) it show and knocks out GFP expression cassettes again by homologous recombination, obtains missing gE genes the 13rd~1298 altogether
PRV AH02LA (Δ gE) strain of 1286bp nucleotides.
Fig. 4, transfer vector pPRV (AH02LA)-GFP (TK-) structure chart.
Fig. 5, transfer vector pPRV (AH02LA)-TK Δs structure chart.
Fig. 6, pseudorabies virus LA1206 strains structure schematic diagram.(A) it show the gene of PRV AH02LA (Δ gE) strain
Group, ULRefer to unique long area, UsRefer to unique short area, IR and TR refer to internal and terminal repeat respectively.(B) it show same by upstream
Source arm Δ TK-H1 and downstream homology arm Δ TK-H2 carries out the partial sequence that homologous recombination replaces GFP expression cassettes TK genes.
(C) it show and knocks out GFP expression cassettes again by homologous recombination, obtains missing gE the 13rd~1298 common 1286bp cores of gene
The LA1206 strains of the 184th to 530 common 347bp nucleotides of thuja acid and TK genes.
The growth characteristics of cultured of Fig. 7, LA1206-80 strain and parental virus compares.A:Infect on ST cell postoperative infection cells
Viral titre in clear liquid;B:Cell-associated viral virus titer after infection ST cells.
Embodiment
The present invention is further illustrated below by way of specific embodiment, but scope and spirit of the present invention are not limited to listed reality
Apply example.
Embodiment one, the structure of pseudorabies virus gE gene-deleted strains and identification
1st, the acquisition of transfer vector
It is artificial synthesized homologous by gE upstream region of gene to knock out the part gE genes of pseudorabies virus PRV AH02LA strains
Arm Δ gE-H1, egfp expression box and gE downstream of gene homology arm Δs gE-H2 compositions genetic fragment, then should
Fragment is cloned into pUC57 carriers (Nanjing Genscript Biotechnology Co., Ltd.), obtain GFP transfer vectors pPRV (AH02LA)-
GFP (gE-), its structure are as shown in Figure 1.GE upstream region of gene homology arm Δs gE-H1 sequence such as SEQ ID No:Shown in 2, gE bases
Because of downstream homology arm Δ gE-H2 sequence such as SEQ ID No:Shown in 3, the same Application No. of sequence of GFP expression cassettes
201510388390.9 patent of invention.
Then it is artificial synthesized to be made up of gE upstream region of gene homology arm Δ gE-H1 and gE downstream of gene homology arm Δs gE-H2
Genetic fragment, the fragment is cloned into pUC57 carriers (Nanjing Genscript Biotechnology Co., Ltd.), obtains transfer vector pPRV
(AH02LA)-gE Δs, its structure are as shown in Figure 2.GE upstream region of gene homology arm Δs gE-H1 sequence such as SEQ ID No:Shown in 2,
GE downstream of gene homology arm Δs gE-H2 sequence such as SEQ ID No:Shown in 3.
2nd, the acquisition of GFP recombinant pseudorabies virus AH02LA strains
Primary chicken embryo fibroblasts (Chicken embryo are prepared using 9~10 age in days SPF chicken embryos
Fibroblasts, CEF), after cell grows up to individual layer, transfected.When being transfected according to conventional calcium phosphate infection protocol, by 0.5
~1 μ g GFP transfer vectors pPRV (AH02LA)-GFP (gE-) the DNA and DNA of 0.2~1 μ g pseudorabies virus AH02LA strains
The primary CEF of cotransfection, homologous recombination (Fig. 3) is carried out, nutrient solution is absorbed after 24 hours, addition contains 10% hyclone and 0.5%
Methylcellulose DMEM culture mediums cover, and continue 24~48h of culture, and picking sends green in the case where wavelength is 488nm ultraviolet excitations
The recombinant virus plaque of color fluorescence, is inoculated into fresh CEF, so repeats more than 3 circulations, obtains the recombinant virus of purifying,
It is named as PRV AH02LA (Δ gE)-GFP strains.Using the DNA of PRV AH02LA (Δ gE)-GFP strains as template, using pair of primers
(sense primer PRV gE site ckeck F sequences are:5’-TCTGGAGGGGCCCTCGCCGA-3’;Anti-sense primer PRV gE
Site ckeck R sequences are:5 '-AGAGAGAGGACGGAGGCGTGTCATC-3 ') PCR amplification by gE upstream region of gene homology arms
(Δ gE-H1), the glimmering protein expression box (GFP) of green and gE downstream of gene homology arm composition genetic fragment (Δ gE-H2), will expand
Increase production thing and carry out electrophoresis and sequencing, to verify whether sequence is correctly inserted into.PCR reaction systems (table 1) and response procedures are such as
Under.
The μ l PCR reaction systems of table 1 25
LA Taq archaeal dna polymerases, 2 × GC Buffer II in PCR reaction systems are purchased from Takara companies.
Reaction system is mixed, enters performing PCR amplification, response procedures are as follows:94 DEG C of pre-degeneration 4min;94 DEG C denaturation 40s, 57
DEG C annealing 40s, 72 DEG C extension 4min30s, 30 circulation;72 DEG C of extension 10min.PCR primer is subjected to 1% Ago-Gel electricity
Swimming, detects whether 4585bp or so purpose band and is cut, and is reclaimed, will reclaimed using DNA gel QIAquick Gel Extraction Kit
Product send Huada gene company to be sequenced.
After qualification result shows that recombinant virus PRV AH02LA (Δ gE)-GFP strains enter performing PCR amplification using above-mentioned primer,
4585bp or so purpose product is obtained, sequencing results are correct, and the recombinant virus is by pseudorabies virus AH02LA
The 13rd to 1298 common 1286bp nucleotides of strain gE genes, which are replaced, inserts what GFP expression cassettes (Fig. 3) obtained afterwards, complete with expection
It is complete consistent.
3rd, the acquisition and identification of pseudorabies virus gE gene-deleted strains
Take the DNA and 700~2000ng of 1~3 μ g recombinant viruses PRV AH02LA (Δ gE)-GFP strains pPRV
(AH02LA) DNA of-gE Δs, according to conventional calcium phosphate infection protocol Transfected primary CEF, second of homologous recombination is carried out, to knock out
GFP expression cassettes (Fig. 3).Absorb nutrient solution within 24 hours after cotransfection, add containing 10% hyclone and 0.5% methylcellulose
DMEM culture mediums cover, and continue 24~48h of culture, and in the case where wavelength is 488nm ultraviolet excitations, picking does not send green fluorescence
Virus plaques are inoculated with fresh CEF, so repeatedly 3~5 circulations, obtain virus after purification, are named as PRV AH02LA (Δs
GE) strain, and as kind of a poison.The DNA of PRV AH02LA (Δ gE) strain is extracted as template, using primer PRV gE site
Ckeck F and PRV gE site ckeck R enter performing PCR amplification, detect whether 2937bp or so purpose band and by its
Cut, reclaimed using DNA gel QIAquick Gel Extraction Kit, and carry out sequencing.
As a result show, the special of 2900~3000bp is obtained using PRV AH02LA (Δ gE) strain DNA as template PCR amplifications
Property fragment, sequencing result is with expected consistent, i.e. the 13rd to 1298 common 1286bp nucleotides of gE genes are by successful knockout.
Embodiment two, the structure of the dual-gene gene-deleted strain of pseudorabies virus gE, TK and identification
1st, the acquisition of transfer vector
To continue to knock out the part of TK gene of pseudorabies virus PRV AH02LA (Δ gE) strain, send Nanjing Jin Sirui biological
Science and Technology Ltd. is artificial synthesized by TK upstream region of gene homology arm Δs TK-H1, egfp expression box (GFP) and TK genes
The genetic fragment of downstream homology arm Δ TK-H2 compositions, is then cloned into pUC57 carriers by the fragment, obtains GFP transfer vectors
PPRV (AH02LA)-GFP (TK-), its structure are as shown in Figure 4.TK upstream region of gene homology arm Δs TK-H1 sequence such as SEQ ID
No:Shown in 4, TK downstream of gene homology arm Δs TK-H2 sequence such as SEQ ID No:Shown in 5, the sequence of GFP expression cassettes is the same as application
Number it is 201510388390.9 patents of invention.
Send Nanjing Genscript Biotechnology Co., Ltd. artificial synthesized by TK upstream region of gene homology arm Δ TK-H1 and TK genes
The genetic fragment of downstream homology arm Δ TK-H2 compositions, is then cloned into pUC57 carriers by the fragment, obtains transfer vector pPRV
(AH02LA)-TK Δs, its structure are as shown in Figure 5.
2nd, the acquisition of GFP recombinant pseudorabies virus PRV AH02LA (Δ gE) strain
Primary chicken embryo fibroblasts (Chicken embryo are prepared using 9~10 age in days SPF chicken embryos
Fibroblasts, CEF), after cell grows up to individual layer, transfected.When being transfected according to conventional calcium phosphate infection protocol, by 0.5
~1 μ g GFP transfer vectors pPRV (LA-A)-GFP (TK-) DNA and 0.2~1 μ g pseudorabies virus PRV AH02LA (Δ gE)
The primary CEF of DNA cotransfections of strain, homologous recombination (Fig. 6) is carried out, nutrient solution is absorbed after 24 hours, addition contains 10% hyclone
Covered with the DMEM culture mediums of 0.5% methylcellulose, continue 24~48h of culture, picking is 488nm ultraviolet excitations in wavelength
Under send the recombinant virus plaque of green fluorescence, be inoculated into fresh CEF, so repeat more than 3 circulations, obtain the weight of purifying
Group virus, is named as PRV AH02LA (gE-)-GFP (TK-) strain.Using the DNA of PRV AH02LA (gE-)-GFP (TK-) strain as mould
Plate, using pair of primers, (sense primer PRV Δ TK ckeck F sequences are:5’-CGCACCCCGAGGTTGACTTCAA-3’;Under
Swimming primer PRV Δ TK ckeck R sequences is:5 '-TTGTACGCGCCGAAGAGGGTGT-3 ') PCR amplification by TK upstream region of gene
The gene piece of homology arm (Δ TK-H1), the glimmering protein expression box (GFP) of green and TK downstream of gene homology arms (Δ TK-H2) composition
Section, amplified production is subjected to electrophoresis and sequencing, to verify whether sequence is correctly inserted into.PCR reaction systems (table 2) and reaction
Program is as follows.
The μ l PCR reaction systems of table 2 25
LA Taq archaeal dna polymerases, 2 × GC Buffer II in PCR reaction systems are purchased from Takara companies.
Reaction system is mixed, enters performing PCR amplification, response procedures are as follows:94 DEG C of pre-degeneration 4min;94 DEG C denaturation 40s, 58
DEG C annealing 40s, 72 DEG C extension 2min30s, 30 circulation;72 DEG C of extension 10min.PCR primer is subjected to 1% Ago-Gel electricity
Swimming, detects whether 2200bp or so purpose band and is cut, and is reclaimed, will reclaimed using DNA gel QIAquick Gel Extraction Kit
Product send Huada gene company to be sequenced.
Qualification result shows that recombinant virus PRV AH02LA (gE-)-GFP (TK-) strains enter performing PCR amplification using above-mentioned primer
Afterwards, 2200bp or so purpose product has been obtained, sequencing results are correct, and the recombinant virus is by pseudorabies virus PRV
The common 347bp nucleotides replacement of TK genes the 184th to 530 of AH02LA (Δ gE) strain obtains after inserting GFP expression cassettes (Fig. 6)
, it is completely the same with expection.
3rd, the acquisition and identification of the dual-gene gene-deleted strains of pseudorabies virus gE, TK
Take the DNA and 700~2000ng of 1~3 μ g recombinant virus PRV AH02LA (gE-)-GFP (TK-) strain pPRV
(AH02LA) DNA of-TK Δs, according to conventional calcium phosphate infection protocol Transfected primary CEF, second of homologous recombination is carried out, to knock out
GFP expression cassettes (Fig. 6).Absorb nutrient solution within 24 hours after cotransfection, add containing 10% hyclone and 0.5% methylcellulose
DMEM culture mediums cover, and continue 24~48h of culture, and in the case where wavelength is 488nm ultraviolet excitations, picking does not send green fluorescence
Virus plaques are inoculated with fresh CEF, so repeatedly 3~5 circulations, obtain virus after purification, are named as PRV LA1206 strains, and
As kind of a poison.The DNA of PRV LA1206 strains is extracted as template, using primer PRV Δ TK ckeck F and PRV Δ TK ckeck
R enters performing PCR amplification, detects whether 347bp purpose band and is cut, and is reclaimed using DNA gel QIAquick Gel Extraction Kit, and
Carry out sequencing.
As a result show, 300~400bp specific fragment obtained using PRV LA1206 strains DNA as template PCR amplifications,
Sequencing result is with expected consistent, i.e. the 184th to 530 common 347bp nucleotides quilts of TK genes of PRV AH02LA (Δ gE) strain
Successful knockout.
4th, the passage of pseudorabies virus LA1206 strains kind poison
Further to improve the security of pseudorabies virus LA1206 strains, pseudorabies virus LA1206 strain kind poison is existed
Continuous passage is carried out on CEF, every 5 generation preserves batch of seeds, passed to for the 120th generation altogether, wherein from the 75th generation to the 80th generation system through even
Continue 5 generation picking single virus Plaque Clones and obtain F80 generations.The malicious 1st generation of pseudorabies virus LA1206 strain kinds is designated as pseudoabies
The viral malicious F1 generation of LA1206 strains kind, other the like.The seed that each generation preserves is put -70 DEG C and stored for future use.
5th, the measure of the gC and gD gene orders of pseudorabies virus LA1206 strains
Type B error hydrophobin LA1206 strain kinds malicious F2 generations and the DNA in F80 generations, itself gC and gD gene piece is expanded by PCR
Section, and carry out sequencing.PRV ZJ01 strains first in GenBank
(GenBank is logged in:KM061380.1) whole genome sequence, using Vector NTI softwares, 2 couples of PCR are designed altogether
Primer (such as table 3), the amplified fragments of these primers cover PRV main protection antigen gC and gD gene order.It is all to set
The primer of meter is synthesized by Nanjing Genscript Biotechnology Co., Ltd..
Table 3 expands the PCR primer of PRV gC and gD genes
Using the DNA in pseudorabies virus LA1206 strain kinds malicious F2 generations and F80 generations as template, gC and gD gene sequences are expanded respectively
Row.Primer in PCR reaction systems as shown in table 1 is replaced with to the primer in table 3, other are constant.PCR reaction conditions are:94
℃1min;94 DEG C of 30s, annealing 30s (determining annealing temperature according to primer Tm), 72 DEG C of extensions are (true according to amplified fragments size
Determine extension of time), 30 circulations;72 DEG C of extension 5min.After the completion of PCR, with 1% agarose gel electrophoresis identify, cut containing
PCR purpose band gel piece of the same size with expection carries out DNA recovery, send 2 glycoprotein gene fragments of recovery to China
Big genome company is sequenced.
Sequencing result shows that pseudorabies virus LA1206 strain kinds malicious F2 generations are identical with gC with the gD gene orders in F80 generations,
And it is identical with AH02LA strains, there is the characteristic feature of PRV variants, and any variation does not occur in passing on.GC and gD is pseudo- mad
The main protection antigen of dog disease virus, its gene show pseudorabies virus LA1206 strains kind poison not because passage changes
Immunogenicity completely kept.
In pseudorabies virus LA1206 strain kinds malicious F80 generations, are named as pseudorabies virus LA1206-80 strains, i.e. PRV
LA1206-80 strains.
Embodiment three, the identification of the growth characteristics of PRV LA1206-80 strains
By velogen strain PRV AH02LA strains, PRV LA-A strains and PRV LA1206-80 strains respectively using MOI as 0.004 inoculation
Cover with the ST cells of individual layer, put 5%CO2In constant incubator after 37 DEG C of incubation 1h, supernatant is sucked, is washed 3 times using PBS
Afterwards, cell maintenance medium (the DMEM culture mediums (Gibco) for containing 3% hyclone (FBS)) is changed into be cultivated, and respectively at inoculation
0h, 6h, 12h, 24h, 36h, 48h and 72h determine in infection cell supernatant that cell combines in free virus and infection cell afterwards
The content of venereal disease poison.
The free virus content of infection cell supernatant is to be operated in accordance with the following methods:At the appointed time put and receive respectively
Collect infection cell supernatant 1ml, 376 × g centrifugation 5min and take 100 μ l supernatants, add in 900 μ l DMEM culture mediums and mix, then
100 μ l are therefrom drawn into 900 μ l DMEM culture mediums, repeat above step, i.e., 10~10 are made to infection cell supernatant9Times
Than dilution.Viral dilution liquid is inoculated in 96 porocyte plates of the individual layer ST cells being paved with advance, each dilution factor makees 8 weights
It is multiple, 37 DEG C of incubation 2h, virus liquid is discarded, (DMEM containing 3% hyclone (FBS) is trained 100 μ l of addition cell maintenance medium per hole
Support base (Gibco)).Start to observe cytopathy situation after 12h, Continuous Observation 3 days, virus is calculated according to Reed-Muench methods
TCID50, count the TCID of all time point virus liquids50, draw growth curve.
The cell-associated viral level detection of infection cell is operated in accordance with the following methods:Suck cell supernatant,
With PBS infection cell 2 times, be resuspended after scraping cells with 2ml DMEM, -70 DEG C with 500 × g after 37 DEG C of multigelations 3 times
5min is centrifuged, takes 100 μ l supernatants to make 10~109Doubling dilution.ST is inoculated with by above-mentioned free virus content detection same procedure
Cell simultaneously determines viral TCID50, count the TCID of all time point virus liquids50, draw growth curve.
The dual-gene gene-deleted strain low virulent strain PRV LA1206- of TK, gE are can be seen that from the growth in vitro curve (Fig. 7) of virus
80 plants have similar growth kinetics to gE gene delection virus PRV LA-A strains and parental virus PRV AH02LA strains, are connecing
24h~48h reaches peak value after kind, although PRV LA1206-80 strains are declined slightly compared with LA-A strains and AH02LA strains, titre is still
Reach 108.0TCID50/ more than mL, the requirement of live vaccine production can be met.
Example IV, the security of PRV LA1206-80 strains
1st, test material
It is 1.1 viral
PRV LA1206-80 strains are inoculated with ST cells, cultivated using the DMEM containing 3% (concentration expressed in percentage by volume) hyclone
Base culture 40 hours, viral cultures are harvested, centrifuging and taking supernatant is as PRV LA1206-80 strain virus liquid after freeze thawing.
The pseudorabies virus malicious F2 of LA1206 strain kinds for virus liquid (preparation method is with PRV LA1206-80 strain virus liquid) and
PRV LA1206-80 strain virus liquid, viral level is respectively 108.0TCID50/ mL and 108.1TCID50/mL;PRV AH02LA strains
Virus liquid, viral level 109.0TCID50/mL;PRV LA-A strain virus liquid, viral level 108.3TCID50/mL.It is viral equal
Put -70 DEG C of preservations.
1.2 diagnostic kit
PRV gE antibody diagnosing reagent kits, CIVTESTSUIS ADVgB HIPRA Products.PRV gB antibody diagnosis tries
Agent box, CIVTESTSUIS ADVgB HIPRA Products.
2nd, experimental animal
Experiment piglet is brood 1 age in days sodium selenite, and its PRV antibody is feminine gender.Diet, the essence of pig are examined before inoculation
Refreshing situation and clinical setting etc., all unsound pigs exclude experiment.It is identified by ear tag number and cage number.With lactation
Sow is raised in isolation environment jointly.Special messenger is responsible for raising, carries out 2 sanitation and hygiene daily.
Test mice is 17~22 grams of Kunming system cleaning grade mouse, purchased from Shanghai Jie Sijie experimental animals Co., Ltd.Raise
Support in clean environment, special messenger raising, daily sanitation and hygiene.
3rd, it is grouped
Brood 1 age in days tests piglet, is randomly divided into 3 groups (A-1, A-2, A-3), every group 4, carries out PRV LA1206 strain kinds
The safety testing in malicious F2 generations, PRV LA1206-80 strains and the inoculation of PRV LA-A strains collunarium.Another age in days of nest 1 tests piglet, with
Machine is divided into 3 groups (B-1, B-2, B-3), every group 4, carries out PRV LA1206 strain kinds malicious F2 generations, PRV LA1206-80 strains and PRV
The safety testing of LA-A strain intramuscular inoculations.
Test mice is randomly divided into 20 groups, every group 4, carries out PRV AH02LA strains, PRV LA-A strains, PRV LA1206 strains
Kind malicious F2 generations, the safety testing of PRV LA1206-80 strains, specific group technology are shown in Table 4.
Table 4, test mice packet
4th, test method
4.1 brood 1 age in days piglet inoculation methods and clinical observation
DMEM culture mediums are applied into PRV LA1206 strain kinds malicious F2 generations, PRV LA1206-80 strains and PRV LA-A strains respectively
It is diluted to 107.0TCID50/ mL, it is each in a manner of collunarium inoculation and intramuscular inoculation respectively to be inoculated with 1 age in days piglet one group (4
Head), inoculum concentration is 1mL/ heads, is specifically shown in Table 5.From inoculation day to after being inoculated with 14 days, the body temperature of daily measurement experiment piglet, observation
Diet and mental status and clinical symptoms.
4.2 mouse inoculation methods and observation
By PRV AH02LA strains and PRV LA1206 strain kinds malicious F2 generations, PRV LA1206-80 strains and PRV LA-A strains point
Not Ying Yong DMEM culture mediums be diluted to 106.0TCID50/ 0.2mL, then suitable concn is diluted to DMEM culture mediums respectively, with subcutaneous
Injection system is inoculated with, each virus inoculation amount such as table 4, and the inoculation volume of virus liquid is 0.2mL/.From inoculation day to after being inoculated with 14
My god, viewing test dead mouse situation.The median lethal dose to mouse is calculated by Reed and Muench methods.
5th, result of the test
5.1 1 age in days piglets results
Each strain the results are shown in Table 5 to the safety testing of piglet.The PRV LA-A strains of missing gE genes resist to 1 age in days PRV
Body feminine gender piglet still has stronger pathogenicity, after TK and gE Gene Doubles missing is carried out its (i.e. PRV LA1206 strains kind malicious F2 generations)
Pathogenicity is remarkably decreased, but either collunarium inoculation or intramuscular injection inoculation all causes the body temperature of test pig to raise, and 4 test pigs
In there is 1 hair to die of illness to die (table 4), show still there is virulence, and after continuous passage to F80 generations, either collunarium or flesh
Note inoculation does not all cause experiment temperature of pig body rise, and no morbidity is dead, shows continuous passage further by the dual-gene missings of TK and gE
Strain causes weak, it was demonstrated that PRV LA1206-80 strains have good security.
The safety testing packet of the age in days piglet of table 51 and result
5.2 mouse test results
LD of the PRV AH02LA strains to mouse50For 102.57TCID50, LD of the PRV LA-A strains to mouse50For
104.96TCID50, PRV LA1206 strain kinds malicious F2 generations and PRV LA1206-80 strains are with 106.0TCID50Mice Inoculated does not cause extremely
Die.
The preservation information of PRV LA1206-80 strains is as follows:
Depositary institution:China Committee for Culture Collection of Microorganisms's common micro-organisms center.
Unit address:Institute of microbiology of the Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 Chinese Academy of Sciences.
Join the biomaterial (strain) of Ju:PRV LA1206-80.
Classification And Nomenclature:Porcine herpesvirus 1.
Preserving number:CGMCC No.14329.
Preservation date:On July 24th, 2017.
Embodiment five, the immune efficacy of PRV LA1206-80 strains
1st, test material
1.1 viruses and pseudorabies living vaccines
PRV LA1206-80 strain virus liquid, viral level 108.1TCID50/mL。
Pseudorabies living vaccines (Bartha K61 strains), purchased from Nanjing Tianbang Bio-industry Co., Ltd., batch 150826.
PRV AH02LA strains, for challenge test, to the LD of 45 age in days PRV feminine gender pigs50For 106.5TCID50。
1.2 diagnostic kit
PRV gE antibody diagnosing reagent kits and PRV gB antibody diagnosing reagent kits, from the prosperous biotechnology of Beijing Ai Deshi members
Co., Ltd (IDEXX) company.
2nd, experimental animal
28~35 age in days sodium selenites 24, its PRV antigen and PRV gE are feminine gender, pig breeding and breathing with gB antibody
Distress syndrome virus (PRRSV), CSFV (SFV), porcine circovirus 2 type (PCV2) and O-shaped foot and mouth disease virus (FMDV
(O)) antigen and antibody are feminine gender.Diet, mental status and clinical setting of pig etc., all unsound pigs are examined before inoculation
Only exclude experiment.It is identified by ear tag number and cage number with circle number.The sub-cage rearing in isolation environment.Feed is full price
Mixed feed (commercially available prod), drink water and respectively fed once for running water, the daily morning and afternoon.Special messenger is responsible for raising, enters daily
2 sanitation and hygiene of row.
3rd, it is grouped
Experimental animal once introduces, and is randomly divided into A~F groups, every group 4, is specifically shown in Table 6.
4th, test method and the index of research
(1) test method
It is immune:PRV LA1206-80 strain virus liquid and pseudorabies living vaccines (Bartha K61 strains) application is sterile
DMEM nutrient solutions are diluted to suitable concentration, intramuscular injection, 2mL/ heads, A groups, B groups and component C and are not inoculated with 1000TCID50、
10000TCID50And 100000TCID50PRV LA1206-80 strain virus liquid, D groups inoculation 100000TCID50Pseudoabies
Live vaccine (Bartha K61 strains), every intramuscular injection 2mL DMEM liquid (table 6) of E, F group.
Table 6, the packet of animal immune challenge test
Group | Immunizing dose | It is inoculated with strain |
A groups | 1000TCID50 | PRV LA1206-80 strains |
B groups | 10000TCID50 | PRV LA1206-80 strains |
C groups | 100000TCID50 | PRV LA1206-80 strains |
D groups | 100000TCID50 | Pseudorabies living vaccines (Bartha K61 strains) |
E groups | Blank control | / |
F groups | Attack malicious control | / |
Attack poison:All pigs in addition to blank control group attack poison in 1 week after inoculation, using PRV AH02LA strains, with 2LD50/
Head collunarium attacks poison, every 2mL, is observed 14 days after attacking poison.
Serum gB and gE antibody test:Before immune, attack before poison and (attacked after poison 14 days) three time points at the end of attacking poison
All pig blood serum samples are taken, PRV gE and gB antibody is detected using kit.
Clinicing symptom observation:All experiment pigs observe spirit, diet and various respiratory systems, nervous system daily
With systemic clinical manifestation.
Measurement of bldy temperature:Since before inoculation, to off-test (attack poison after 14 days), all pigs measure body temperature once daily
(rectal temperature).
Toxin expelling situation detects:Before attacking poison, attack after poison to off-test (attack poison after 14 days), gather pig nose swab sample daily
Product, sample put -70 DEG C of preservations, are inoculated with BHK-21 cell observations lesion after doubling dilution to determine whether discharge virus during detection.
(2) index of research
The incidence of disease, the death rate, body temperature rising condition, toxin expelling situation, serum antibody sun turn situation.
5th, result of the test
PRV gB and the gE antibody of all test pigs is feminine gender before inoculation, and blank control pig (E groups) is to during off-test
PRV gB and gE antibody be feminine gender, A groups (before attacking poison) at 1 week after inoculation, B groups, all test pigs of C groups and D groups
PRV gB antibody is the positive, and it is the positive to attack all immune group pigs after poison and attack the PRV gE antibody of malicious control group survival pig
(table 7).
Table 7, Immunization test pig serum antibody sun turn situation statistical form
After attacking poison, blank control group pig is dead without morbidity, no body temperature rise, does not detect toxin expelling;Attack malicious 4 pigs of control group
All occur subtracting food since after attacking poison the 2nd day, spirit is depressed, sneezing, and symptom, the body temperature such as rhinorrhea and expiratory dyspnea all rise
Height detects toxin expelling, the 4th~6 day dead successively 3 after poison is attacked to more than 40.5 DEG C from nose swab sample;Show to test
(table 8) is set up in control.A groups, B groups, all test pigs of C groups without clinical symptoms, no body temperature rise, do not detect toxin expelling, show PRV
LA1206-80 strains can produce protection completely to PRV variants;D groups test pig has 1 pig clinical symptoms occur without death, 4
There is body temperature rise in pig, detects toxin expelling from nose swab sample, shows that PRV Bartha K61 strains only produce part guarantor
Protect (table 8).
Table 8, Immunization test pig clinical setting statistical form
In summary, the equal complete guarantor that can be produced to the AH02LA strains of PRV street strains of pig is immunized in PRV LA1206-80 strains
Shield, as little as most 1000TCID50Inoculum concentration it is immune after can also resist morbidity and toxin expelling, and 100000TCID50PRV Bartha
K61 strains can only generating unit code insurance shield, it is impossible to prevent body temperature react and toxin expelling, LA1206-80 strains are as vaccine strain to variant
Protecting effect is significantly better than Bartha K61 strains.Live vaccination pig detection PRV gB prepared by PRV LA1206-80 strains resist
Body, PRV gE antibody not being detected, being a kind of DIVA vaccines that can differentiate vaccine immunity animal and wild virus infection animal, it is promoted should
With will be very beneficial for carrying out the purification of PRV variants in pig farm, have a extensive future.Due to LA1206-80 strains, virulence significantly drops
It is low, to 1 age in days piglet no pathogenicity, therefore it is the vaccine candidate low virulent strain with higher-security, available for newborn piglet
Early immune, the infection of wild poison is blocked as early as possible.
SEQUENCE LISTING
<110>Jiangsu Province Agriculture Science Institute
<120>The dual-gene missing low virulent strain of pseudorabies virus and its application
<130> 20171103
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 963
<212> DNA
<213>PRV AH02LA strains
<400> 1
atgcgcatcc tccggatcta cctcgacggc gcctacggca ccggcaagag caccacggcc 60
cgggtgatgg cgctcggcgg ggcgctgtac gtgcccgagc cgatggcgta ctggcgcact 120
ctgttcgaca cggacacggt ggccggtatt tacgatgcgc agacccggaa gcagaacggc 180
agcctgagcg aggaggacgc ggccctcgtc acggcgcagc accaggccgc cttcgcgacg 240
ccgtacctgc tgctgcacac gcgcctggtc ccgctcttcg ggcccgcggt cgagggcccg 300
cccgagatga cggtcgtctt tgaccgccac ccggtggccg cgacggtgtg cttcccgctg 360
gcgcgcttca tcgtcgggga catcagcgcg gcggccttcg tgggcctggc ggccacgctg 420
cccggggagc cccccggcgg caacctggtg gtggcctcgc tggacccgga cgagcacctg 480
cggcgcctgc gcgcccgcgc gcgcgccggg gagcacgtgg acgcgcgcct gctcacggcc 540
ctgcgcaacg tctacgccat gctggtcaac acgtcgcgct acctgagctc ggggcgccgc 600
tggcgcgacg actgggggcg cgcgccgcgc ttcgaccaga ccgtgcgcga ctgcctcgcg 660
ctcaacgagc tctgccgccc gcgcgacgac cccgagctcc aggacaccct cttcggcgcg 720
tacaaggcgc ccgagctctg cgaccggcgc gggcggccgc tcgaggtgca cgcgtgggcg 780
atggacgcgc tcgtggccaa gctgctgccg ctgcgcgtct ccaccgtcga cctggggccc 840
tcgccgcgcg tctgcgccgc ggccgtggcg gcgcaggcgc gcggcatgga ggtgacggag 900
tccgcgtacg gcgaccacat ccggcagtgc gtgtgcgcct tcacgtcgga gatgggggtg 960
tga 963
<210> 2
<211> 1023
<212> DNA
<213> artificial
<220>
<223>GE upstream region of gene homology arm Δs gE-H1
<400> 2
tgtttctgga ggggccctcg ccgagcaact acagcgggcg cgtggagctg ctgcgcctcg 60
accccaagcg cgcctgctac acgcgcgagt acgccgccga gtacgacctc tgcccccgcg 120
tgcaccacga agccttccgc ggctgcctgc gcaagcgcga gccgctcgcc cggcgcgcgt 180
ccgccgcggt ggaggcgcgc cggctgctgt tcgtctcgcg cccggcctcg ggggacgcgg 240
ggtcgtacgt gctgcgggtc cgcgtgaacg ggaccacgga cctctttgtg ctgacggccc 300
tggtgccgcc gagggggcgc cccgtcccca cgtcgccgcc cgcggacgag tgccggcccg 360
tcgtcggatc gtggcacgac agcctgcgcg tcgtggaccc cgccgaggac gccgtgttca 420
ccacccagcc cccgcccgag cccgagccgc cgacgacccc cgcgcccccc cgggggaccg 480
gcgccacccc cgagccccga tcggacgagg aggaggaggt gacgcggaga cgacgacgcc 540
gactgacccc cgcgcccggg accctggacg cgaacggcac gatggtgctg aacgccagcg 600
tcgtgtcgcg cgtcctgctc gccgccgcca acgccacggc gggcgcccgg agccccggga 660
agatagccat ggtgctgggg cccacgatcg tcgtcctcct gatcttcctg ggcgggatcg 720
cctgcgtggc ccggcgctgc gcgcggaatc gcatctaccg gccgcgaccc gggcgcggat 780
cggcggtcca tgcggcgccc ccgcggcgcc cgcccccaac cccggtcgcc ggggcgcccg 840
tcccccagcc caagatgacg ttggccgagc tgcgccagaa gctcgccacc atcgcagaag 900
aacaataaaa aggtggtgtt tgcataattt tgtgggtggc gttttatctc cgtccgcgcc 960
gttttaaacc tgggcacccc cgcgagtctc gcacacaccg gggttgagac catgcggccc 1020
ttt 1023
<210> 3
<211> 1113
<212> DNA
<213> artificial
<220>
<223>GE downstream of gene homology arm Δs gE-H2
<400> 3
gctggcgctg ggctccttcg tgatgacgtg cgtcgtcggg ggggccatct ggctctgcgt 60
gctgtgctcc cggcgccggg cggcctcgcg gccgttccgg gtgccgacgc gggcgcggac 120
gcacatgctc tctccggtgt acaccagcct gcccacgcac gaggactact acgacggcga 180
cgacgacgac gacgaggagg cgggcgtcat ccgccggcgg cccgcctccc ccagcggaga 240
cagcggctac gaggggccgt acgcgagcct ggaccccgag gacgagttca gcagcgacga 300
ggacgacggg ctgtacgtgc gccccgagga ggcgccccgc tccggcttcg acgtctggtt 360
ccgcgatccg gagaaaccgg aagtgacgaa tggacccaac tatggcgtga ccgccaaccg 420
cctgttgcat gtcccgcccc gctaaaatac cgggagaacc ggtccgcccg cattccgaca 480
tgcccggcgc cgcctccgtc gacatggaca cgtttgaccc cagcgccccc gtcccgacga 540
gcgtctcgaa cccggccgcc gacgtcctgc tggcccccaa gggaccccgc tccccgctgc 600
gcccccagga cgactcggac tgctactaca gcgagagcga caacgagacg cccagcgagt 660
tcctgcgccg cgtgggacgc cggcaggcgg cgcgtcggag acgccgccgc tgcctgatgg 720
gcgtcgcgat cagcgccgcc gcgctggtca tctgctcgct gtccgcgcta ctcgggggca 780
tcgtcgccag gcacgtgtag cgagcgagcg agcgaacggg agcgggggcc cgcccccatc 840
cgccgcgccc aggagagggg ggagagagcg gggggttggg cgcgccacgt ggtgtgggca 900
cggactcgga cttgtcacaa taaatgggcc ccggcgtgtc cgggcgcaca cagcagcctt 960
cctctcctcc gcgtctctgt tccgcccgtc tctcgccgga ctcttcttct ccaccgcctc 1020
caccgtcgca gttgtcgcga gcgcgttcgc accatggggg tgacggccat caccgtggtc 1080
acgctgatgg acggggccgg gcgcatcccc gcc 1113
<210> 4
<211> 1204
<212> DNA
<213> artificial
<220>
<223>TK upstream region of gene homology arm Δs TK-H1
<400> 4
cgtcgtaggc gagcgccacg tcgttcttgg cgatctgcac ctcgcggccc tcgtccgcgg 60
ccgcgaccgc ctcgggcgcc tcctcggcgg cgcgcgccgc gtccgcctcc tcggcggcgc 120
gcgccgtctc ctcgagcacc acgagcgcct cggccacgcg ctccacctgc cgctccagcg 180
gccgcagctg ctcgtccacc tcggcctcga ggcgcgcgcc cgcggccatg gcgttgtcca 240
gcgccgcggc ggccgcgcgg cggcgcgcgt tcgcgtgcgc cagcgcgagg cgcgcgtcga 300
ggccctcgcc gaagcccggg cgggcccaga agcccacggg gaacgggggc gcgatgaagt 360
ggcgcgcgct gcccgggatc gcagcggcct cgaaggcgaa ccacgcgcgg tccatggcgc 420
ggggggacat gggccgcgcg gcggcgcgcg ccgccttatc atccccgctc cccgccgccg 480
cccggcccgg ccccgcgcgc gccgcgatcg cgatcaccgc cgcggcccgg cgacgtactc 540
ggcgaggccg cgcacggtcg cggccatcgc gctcgcgttg ccgcgcgtct gggtgcaggg 600
caggcgcgtc acgtcgagca cgcgcatgct ccgctgggcc acaaacacca gcaggggcac 660
gagcgtgatc tcctcgccgc ccgggggcac ggcggcggcg aggaggcgcg ccgagtcgcg 720
cagctggcac agcccctcgt gccgctgccc gcgcttgctg ggcgtgttga ggttccgggg 780
gaagcggcac gtcttgagct cgatgaggaa gcacaggtgc gggcccgccc ccagccgcac 840
cacgcacacg cagtcggggc ggcgcacccc gaggttgact tcaaaggcca gggtcaagga 900
cgccttctta agcgtctctc ggggaagccc gaagagactc tcgccgtacg cggacgggtc 960
gcgtcgcagg cgttcgtaga agcggttgtg gcagcggatc cccgcccgga agcgcgccgg 1020
gatgcgcatc ctccggatct acctcgacgg cgcctacggc accggcaaga gcaccacggc 1080
ccgggtgatg gcgctcggcg gggcgctgta cgtgcccgag ccgatggcgt actggcgcac 1140
tctgttcgac acggacacgg tggccggtat ttacgatgcg cagacccgga agcagaacgg 1200
cagc 1204
<210> 5
<211> 1216
<212> DNA
<213> artificial
<220>
<223>TK downstream of gene homology arm Δs TK-H2
<400> 5
gctcacggcc ctgcgcaacg tctacgccat gctggtcaac acgtcgcgct acctgagctc 60
ggggcgccgc tggcgcgacg actgggggcg cgcgccgcgc ttcgaccaga ccgtgcgcga 120
ctgcctcgcg ctcaacgagc tctgccgccc gcgcgacgac cccgagctcc aggacaccct 180
cttcggcgcg tacaaggcgc ccgagctctg cgaccggcgc gggcggccgc tcgaggtgca 240
cgcgtgggcg atggacgcgc tcgtggccaa gctgctgccg ctgcgcgtct ccaccgtcga 300
cctggggccc tcgccgcgcg tctgcgccgc ggccgtggcg gcgcaggcgc gcggcatgga 360
ggtgacggag tccgcgtacg gcgaccacat ccggcagtgc gtgtgcgcct tcacgtcgga 420
gatgggggtg tgaccctcgc ccctcccacc cgcgccgcgg ccggatggag accgcgacgg 480
aggcaacgac gacggcgtgg gagggggctc ggggcgcgta taaagccatg tgtatgtcat 540
cccaataaag tttgccgtgc ccgtcaccat gcccgcgtcg tccgtgcgcc tcccgctgcg 600
cctcctgacc ctcgcgggcc tcctggccct cgcgggggcc gccgccctcg cccgcggcgc 660
gccgcagggt gggccgccct cgccgcaggg gggtcccgcg cccaccgcgg cgcccgcgcg 720
cgggcccacc ctgttcgtcc tggacggcga cggctccgcg tggttcgtct tccagctcgg 780
cgggctgggg gcgctcaacg acacgcgcat ccgcgggcac ctgctcggcc ggtacctcgt 840
ctcgtaccag gtggtgcccc cgcccgtctc cgcgtggtac tttgtgcagc gcccgcgcga 900
gcgcccgcgc ctctcggggc cgccctcggg cgcggagctc gtggccttcg acgcgcccgg 960
cgtccggcgc acgtacacca cggcggcggt gtggcccgcg gaggtggccg tcctcgcgga 1020
cgcggaggcg cgctgccccg cggccgtctt caacgtgacg ctgggcgagg ccttcctcgg 1080
cctgcgcgtc gcgctgcgct ccttcctgcc gctggaggtc atcatctccg ccgagcggat 1140
gcgcatgatc gcgcccccgg cgctcggctc ggacctggag ccgccgggcc cgcccgcggg 1200
ccgcttccac gtgtac 1216
Claims (6)
1. the dual-gene missing low virulent strain of pseudorabies virus, is pseudorabies virus LA1206-80 strains, deposit number is:CGMCC
No.14329。
2. application of the dual-gene missing low virulent strain of pseudorabies virus described in claim 1 in pseudorabies vaccines are prepared.
3. using the dual-gene missing low virulent strain of pseudorabies virus described in claim 1 as the vaccine of active component.
4. vaccine according to claim 3, it is characterised in that the virus liquid of the dual-gene missing low virulent strain of pseudorabies virus is adopted
Prepare with the following method:Pseudorabies virus LA1206-80 strains are inoculated with ST cells, cultivated using the DMEM containing hyclone
Base culture 36~48 hours, viral cultures are harvested, centrifuging and taking supernatant is as pseudorabies virus LA1206-80 strains after freeze thawing
Virus liquid.
5. vaccine according to claim 4, it is characterised in that the vaccine is live vaccine.
6. a kind of recombinant vector live vaccine, it is characterised in that its active component is double in pseudorabies virus described in claim 1
Insert what is obtained after external source protective antigen gene expression cassette in gene delection low virulent strain genome.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711083192.7A CN107828741B (en) | 2017-11-07 | 2017-11-07 | Pseudorabies virus double-gene deletion attenuated strain and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711083192.7A CN107828741B (en) | 2017-11-07 | 2017-11-07 | Pseudorabies virus double-gene deletion attenuated strain and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107828741A true CN107828741A (en) | 2018-03-23 |
CN107828741B CN107828741B (en) | 2021-01-12 |
Family
ID=61654636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711083192.7A Active CN107828741B (en) | 2017-11-07 | 2017-11-07 | Pseudorabies virus double-gene deletion attenuated strain and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107828741B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439634A (en) * | 2018-11-09 | 2019-03-08 | 江苏省农业科学院 | Pseudorabies virus genetic engineering attenuated vaccine strain and its application |
CN110387354A (en) * | 2019-08-16 | 2019-10-29 | 江苏省农业科学院 | Pseudorabies virus Attenuation strain and its application |
CN114717204A (en) * | 2022-03-08 | 2022-07-08 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | Replication-defective pseudorabies virus and construction method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102888383A (en) * | 2012-04-27 | 2013-01-23 | 肇庆大华农生物药品有限公司 | Recombinant porcine pseudorabies virus TK/gE double-gene deletion strain |
CN104130982A (en) * | 2014-04-30 | 2014-11-05 | 肇庆大华农生物药品有限公司 | Recombinant pseudorabies virus, construction method and application thereof |
CN104250640A (en) * | 2014-08-22 | 2014-12-31 | 普莱柯生物工程股份有限公司 | Porcine pseudorabies virus gene deletion strain, vaccine composition, preparation method and application thereof |
CN104928261A (en) * | 2015-07-03 | 2015-09-23 | 江苏省农业科学院 | Pseudo-rabies virus LA-A strain and establishing method and application thereof |
CN105018433A (en) * | 2014-04-18 | 2015-11-04 | 普莱柯生物工程股份有限公司 | Porcine pseudorabies virus gene deletion strain, vaccine composition and preparation method and application thereof |
-
2017
- 2017-11-07 CN CN201711083192.7A patent/CN107828741B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102888383A (en) * | 2012-04-27 | 2013-01-23 | 肇庆大华农生物药品有限公司 | Recombinant porcine pseudorabies virus TK/gE double-gene deletion strain |
CN105018433A (en) * | 2014-04-18 | 2015-11-04 | 普莱柯生物工程股份有限公司 | Porcine pseudorabies virus gene deletion strain, vaccine composition and preparation method and application thereof |
CN104130982A (en) * | 2014-04-30 | 2014-11-05 | 肇庆大华农生物药品有限公司 | Recombinant pseudorabies virus, construction method and application thereof |
CN104250640A (en) * | 2014-08-22 | 2014-12-31 | 普莱柯生物工程股份有限公司 | Porcine pseudorabies virus gene deletion strain, vaccine composition, preparation method and application thereof |
CN104928261A (en) * | 2015-07-03 | 2015-09-23 | 江苏省农业科学院 | Pseudo-rabies virus LA-A strain and establishing method and application thereof |
Non-Patent Citations (3)
Title |
---|
中华预防医学会: "《全国预防医学科技成果汇编(1992-1996)》", 31 July 1998, 北京医科大学中国协和医科大学联合出版社 * |
白挨泉等: "《猪伪狂犬病及其防制》", 30 January 2008, 金盾出版社 * |
邢钊等: "《兽医生物制品实用技术》", 31 July 2000, 中国农业大学出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439634A (en) * | 2018-11-09 | 2019-03-08 | 江苏省农业科学院 | Pseudorabies virus genetic engineering attenuated vaccine strain and its application |
CN109439634B (en) * | 2018-11-09 | 2021-11-19 | 江苏省农业科学院 | Pseudorabies virus gene engineering attenuated vaccine strain and application thereof |
CN110387354A (en) * | 2019-08-16 | 2019-10-29 | 江苏省农业科学院 | Pseudorabies virus Attenuation strain and its application |
CN114717204A (en) * | 2022-03-08 | 2022-07-08 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | Replication-defective pseudorabies virus and construction method and application thereof |
CN114717204B (en) * | 2022-03-08 | 2023-12-26 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | Replication-defective pseudorabies virus, construction method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN107828741B (en) | 2021-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109439634B (en) | Pseudorabies virus gene engineering attenuated vaccine strain and application thereof | |
CN102994458B (en) | Porcine pseudorabies virus virulent strain, and gene deletion vaccine strain thereof and applications thereof | |
CN103756977B (en) | Porcine pseudorabies variant gE and gI genetically deficient virus strain and application thereof | |
CN107815441A (en) | A kind of II type Pseudorabies virus attenuated strain and its preparation method and application | |
CN104877972B (en) | A kind of dual-gene gene-deleted strain of recombinant porcine pseudorabies poison gE/gI and its application | |
CN104826103B (en) | A kind of porcine pseudorabies virus vaccine | |
CN106282128B (en) | One plant causes weak porcine pseudorabies virus gene delection attenuated vaccine strain and its application by the passage of cell low temperature and drug screening | |
CN110387354B (en) | Pseudorabies virus passage attenuated strain and application thereof | |
CN103627678B (en) | A kind of porcine pseudorabies virus variant PRV-ZJ01 and application | |
CN104004774A (en) | Swine pseudorabies virus and vaccine composition as well as preparation method and application thereof | |
CN112500458B (en) | Novel variant subunit vaccine of chicken infectious bursal disease virus, preparation method and application thereof | |
CN104830810B (en) | A kind of gene-deleted strains of recombinant porcine pseudorabies poison TK/gE/gI tri- | |
CN106947746B (en) | LDL-T plants of infectious bronchitis of chicken attenuated vaccine strain and its application | |
CN109207436B (en) | Group I type 4 avian adenovirus strain and application thereof | |
CN107828741A (en) | The dual-gene missing low virulent strain of pseudorabies virus and its application | |
CN108066758B (en) | Raccoon dog canine distemper-parvovirus enteritis bigeminal live vaccine and preparation method and application thereof | |
CN111876391A (en) | Feline panleukopenia virus FPV BJ05 strain and application thereof | |
CN107893057A (en) | Chicken infectivity bronchitis virus attenuated strain and its construction method and application | |
CN104928260A (en) | Infectious bovine rhinotracheitis virus IBRV-JN03 isolate and application thereof | |
CN109609468A (en) | A kind of porcine pseudorabies virus of six gene delection, pseudorabies disease vaccine and preparation method | |
CN105727275B (en) | A kind of duck hepatitis bivalent vaccine and preparation method thereof | |
CN111647568A (en) | Reverse genetic vaccine strain of novel variant strain of chicken infectious bursal disease virus and application thereof | |
CN114891753B (en) | Novel duck reovirus passaging attenuated strain and application thereof | |
CN110499296A (en) | A kind of heat-resisting serum 8b type aviadenovirus recombinant vaccine Candidate Strain and its construction method | |
CN102363770A (en) | Recombinant baculovirus capable of expressing porcine circovirus type 2 Cap protein and somatostatin in fusion manner, and subunit vaccine thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |